Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ranbaxy_Laboratories
gptkb:Taro_Pharmaceutical_Industries |
| gptkbp:CEO |
gptkb:Dilip_Shanghvi
|
| gptkbp:country |
gptkb:India
|
| gptkbp:foundedBy |
gptkb:Dilip_Shanghvi
|
| gptkbp:foundedYear |
1983
|
| gptkbp:headquartersLocation |
gptkb:Mumbai
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sun Pharma Group
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
Global
|
| gptkbp:notableProduct |
gptkb:Revital
gptkb:Odomos gptkb:Volini |
| gptkbp:numberOfEmployees |
over 37,000
|
| gptkbp:products |
Active pharmaceutical ingredients
Generic drugs |
| gptkbp:publiclyTraded |
Yes
|
| gptkbp:revenue |
INR 432.6 billion (2023)
|
| gptkbp:servesArea |
Worldwide
|
| gptkbp:stockExchange |
gptkb:NSE
BSE |
| gptkbp:stockSymbol |
gptkb:SUNPHARMA
|
| gptkbp:subsidiary |
gptkb:Ranbaxy_Laboratories
|
| gptkbp:website |
https://www.sunpharma.com/
|
| gptkbp:bfsParent |
gptkb:Sun_Pharmaceutical_Industries
|
| gptkbp:bfsLayer |
6
|